Estrella Immunopharma, Inc.
Clinical-stage biopharma developing T-cell immunotherapies for cancer and autoimmune diseases.
ESLA | US
Overview
Corporate Details
- ISIN(s):
- US2975841048 (+2 more)
- LEI:
- Country:
- United States of America
- Address:
- 5858 HORTON STREET, SUITE 370, 94608 EMERYVILLE
- Website:
- https://www.estrellabio.com/
- Sector:
- Manufacturing
Description
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell immunotherapies for cancer and autoimmune diseases. The company's proprietary technology is the ARTEMIS® (Affinity-optimized T-cell Receptor Engineered for Minimal Signaling) T-cell platform. Its pipeline is centered on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat blood cancers and solid tumors. Estrella aims to translate scientific innovations into next-generation cell therapies to address significant treatment challenges and improve patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Estrella Immunopharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Estrella Immunopharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Estrella Immunopharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
